NCT07224854Active, not recruiting
Epigenetic Signature for CRC Early Detection
A Model of Epigenetic Biomarkers Based on cfDNA 5mC/5hmC for Early Detection of Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
The epiCED is a noninvasive blood-based assay designed for early detection of colorectal cancer (CRC) using circulating cell-free DNA (cfDNA) 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) epigenetic markers. This study leverages retrospective, multi-center cohorts of CRC patients and non-cancer controls to discover and validate a robust cfDNA methylation signature. Small-scale sequencing and machine learning-based modeling will be applied to identify a minimal panel of methylation markers that can accurately discriminate CRC from non-cancer individuals, including early-stage disease. The ultimate goal is to develop a clinically practical, noninvasive screening tool that enables population-level early detection and improves patient outcomes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 3 Nov 2025
- Start date
- 21 Jun 2024
- Primary completion date
- 18 Jun 2028
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Colorectal cancer
- NCT number
- NCT07224854
What you commit to
- Study type: Observational
- Planned participants: 500
- From 21 Jun 2024 to the primary completion date, 18 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent malignancies outside the gastrointestinal tract (unless in complete remission ≥5 years).
- Recent chemotherapy, radiotherapy, or major surgery within 4 weeks prior to blood collection (if prospective samples).
Other illness
- Any condition precluding reliable sample analysis or participation.
Other
- Samples with insufficient volume or poor cfDNA quality.
Who the study is looking for
- Adults aged ≥18 years at the time of sample collection.
- Patients with confirmed CRC or non-cancer controls.
- Availability of retrospective blood samples collected according to institutional protocols.
- Willingness to allow use of de-identified clinical and demographic data.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Nat Medical Ctr Coordinator of this site? Confirm its status | Monrovia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.